Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19
Li Ni , Ling Zhou , Min Zhou , Jianping Zhao , Dao Wen Wang
Front. Med. ›› 2020, Vol. 14 ›› Issue (2) : 210 -214.
Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19
In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.
novel coronavirus (2019-nCoV) / COVID-19 / Chinese traditional patent medicine / Shuanghuanglian oral liquid
| [1] |
|
| [2] |
|
| [3] |
National Health Commission of the People’s Republic of China. Latest update on Novel Coronavirus Pneumonia as of 24:00, February 14, 2020. 2020. in Chinese) (accessed February 15, 2020) |
| [4] |
|
| [5] |
|
Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature
/
| 〈 |
|
〉 |